Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation

NCT00989001 is registered in ClinicalTrials.gov with Advanz Pharma as lead sponsor.

NCT NCT00989001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00989001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation
Lead sponsor
Advanz Pharma
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2009
Completion date
November 30, 2010
Enrollment
217 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation